MAP2K7 and uveal melanoma: It was reported that 80% uveal melanomas have GNAQ or GNA11 mutations, which were potential drivers of MAPK activation; and a randomized phase II trial of selumetinib, a selective MEK inhibitor, has shown prospective therapeutic effect for uveal melanomas (41, 42).